The qualification and use of Citalopram Impurities are essential for maintaining pharmaceutical consistency and ensuring compliance with global regulatory frameworks. These impurity materials—once fully identified, characterized, and qualified—may be used as working standards or secondary reference standards. Internal validation is recommended under FDA and international pharmacopeial guidelines.
We offer a validated selection of Citalopram EP impurities. These impurities are structurally confirmed and analytically validated to meet European Pharmacopoeia (EP) specifications. They support impurity profiling, method development, and batch release testing. Internal qualification ensures their suitability for regulated workflows.
Our catalog includes Citalopram related compounds such as synthetic intermediates, degradation products, and structural analogs. These compounds are essential for forced degradation studies, impurity identification, and analytical method optimization. Regulatory acceptance requires thorough qualification and documentation.
Citalopram impurity reference standards are supplied with validated analytical data and full structural characterization. These standards are used in pharmaceutical research, product development, ANDA and DMF filing, method validation, and genotoxicity assessment. They ensure reproducibility across R&D, formulation development, and quality control environments. Internal validation confirms their ongoing reliability in regulated pharmaceutical applications.
Register to add the product to RFQ list
Already have an account? Log in here
Don’t have an account? Register here
